COMP <GO>
UTHR vs LLY // NET PROFIT MARGIN
United Therapeutics Corporation (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: UTHR 9
— LLY 5
▲ NET PROFIT MARGIN LEADER: UTHR
LAST: $598.72 (+0.87%) • MKT CAP: $25.46B
net-margins
41.90%
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
net-margins
31.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (UTHR VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | UTHR | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.90% | 83.64% | +4.26 | UTHR | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 20.10% | 32.36% | -12.26 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 12.5x | 36.4x | -23.92 | UTHR | /valuation <GO> |
| Free Cash Flow Yield | 4.09% | 2.30% | +1.79 | UTHR | /fcf-yield <GO> |
| Operating Margin | 46.90% | 40.21% | +6.69 | UTHR | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 41.90% | 31.90% | +10.00 | UTHR | /net-margins <GO> |
| Revenue Growth (YoY) | 10.60% | 45.51% | -34.91 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 22.52 | 9.29 | +13.23 | UTHR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 9/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 6.77% | -0.07 | UTHR | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 70.1 | 77.9 | -7.76 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 0.51 | +0.44 | UTHR | /macro-sensitivity <GO> |
| Forward P/E Multiple | 17.8x | 26.3x | -8.45 | UTHR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $25.46B | $1.33T | -$1.31T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | UTHR REV | LLY REV | UTHR GROSS % | LLY GROSS % | UTHR FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.18B | $65.18B | 87.9% | 83.0% | $1.04B | $16.81B |
| FY 2024 | $2.88B | $45.04B | 89.2% | 81.3% | $1.08B | $8.82B |
| FY 2023 | $2.33B | $34.12B | 44.0% | 79.3% | $873.3M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
UTHR // BETA 0.95
LLY // BETA 0.51